The Vaccine Activation Measure (VAM™): Validation of a new segmentation tool for understanding vaccine hesitance and confidence

Moon Z^{1,2}, Auyeung V^{1,2}, Grimmett C², Harley M³, Peters JA³, Bodini S², Gray R², Crawshaw J^{2,4}, Horne R¹

1. Centre of Behavioural Medicine, UCL School of Pharmacy, University College London, UK; 2. Personia Health, a UCL Business Company, UK;

3. AstraZeneca, UK; 4. Ottawa Hospital Research Institute, Canada

Personia Health MAKING THE MOST OF MEDICINES

Introduction

The childhood flu vaccination program in England has been established for many years, but uptake is sub-optimal (45-50%) and there is disparity in uptake across the country. There is a need for urgent targeted interventions and tools to better understand vaccine hesitancy and improve uptake².

Aim

The Vaccine Activation Measure (VAM™) is a new tool which segments people into four activation levels based on their beliefs about vaccines. It was originally validated for COVID-19 Vaccination uptake (N=439). This study aimed to further validate the VAM™, by investigating whether VAM™ scores predict self-reported uptake of vaccination against childhood flu.

Methods

This was a cross-sectional survey of a representative sample of parents in England offered flu vaccination for their child. Parents were recruited through a market research panel and completed a self-reported online survey covering measures around beliefs about vaccines and sociodemographic characteristics (Figures 1 and 2). Participants self-reported whether they had ever accepted or declined the childhood flu vaccination for their child (Figure 3)*.

The VAM™ applies the Necessity Concerns Framework³ to identify the key beliefs influencing vaccine activation and engagement. Vaccine Necessity and Concerns are assessed using the VAX-NC™ questionnaire adapted from the Beliefs about Medicines Questionnaire™⁴. Parents were segmented into 4 categories of vaccine activation, with Level 4 indicating the highest level of activation. To establish the predictive value of the VAM™, a binary logistic regression analysis was run to identify the odds of vaccination at each level of the VAM™, controlling for key sociodemographic characteristics.

Results and Discussion

Data from 1,494 parents of children 2-16 years from England were analysed.






Figure 4: Vaccine Activation Ladder: 4 levels derived from VAM™ scores.



Childhood flu vaccine acceptance was predicated by the VAM™, with higher VAM™ scores associated with higher rates of vaccine uptake. In the logistic regression model, sociodemographic variables accounted for 4% of the variation in vaccination. Inclusion of VAM™ increased this to 52%.

When controlling for gender, ethnicity, household income and education, the odds of being vaccinated were 57 times higher for those at Level 4 compared to those at Level 1. The odds were 2.97 (1.89-4.70) times and 24.6 (12.38-48.89) times higher for those in Level 2 and 3.






Figure 1: Parent demographics for gender, ethnicity and household income.




Figure 2: Child demographic for school cohort.

Figure 3: Parent response on acceptance and willingness to accept vaccination for their child.*

Conclusion

- VAM™ scores strongly predicted childhood flu vaccine uptake
- The VAM™ is a pragmatic new tool to segment people into levels of activation and understand the reasons driving vaccine uptake and refusal
- The VAM™ can be applied in public health interventions to support informed decisions about vaccination

References

- 1. Howell-Jones et al., 2023. BMC Public Health, 23(143).
- 2. Smith et al., 2017. Vaccine, 35(15), 1936-45.
- 3. Horne R et al., 2013. *PLoS One*; 8(12): e80633.
- 4. Horne R et al., 1999. *Psychol Health*; 14(1): 1-24.

* For self-reported uptake, n=118 (8%) had not yet decided whether to vaccinate their child, and therefore their uptake data refers to their intentions to vaccinate.

